Article

eAbstract: Efficacy and Safety of Azithromycin 1.5% Eye Drops for Purulent Bacterial Conjunctivitis in Pediatric Patients

The results of this study found that azithromycin 1.5% eye drops are more effective than tobramycin for treating bacterial conjunctivitis.

Click here to access this third-party resource:

Efficacy and Safety of Azithromycin 1.5% Eye Drops for Purulent Bacterial Conjunctivitis in Pediatric Patients

Journal: The Pediatric Infectious Disease Journal (March 2010)

Authors: Bremond-Gignac D, Mariani-Kurkdjian P, Beresniak A, et al.

Purpose: To evaluate the safety and efficacy of azithromycin 1.5% eye drops for the treatment of purulent bacterial conjunctivitis in children.

Results: Compared to tobramycin 0.3%, with 1 drop every 2 hours for 2 days and then 4 times daily for 5 days, azithromycin 1.5% eye drops twice daily for 3 days “provided a greater bacteriologic cure on day 3 than did tobramycin (P < 0.001) and eradicated bacteria that were defined as resistant, using classical antibiogram.” The authors conclude: “azithromycin 1.5% eye drops leads to a rapid clinical and microbiological cure.”

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
© 2024 MJH Life Sciences

All rights reserved.